To determine whether our PKCA compounds can suppress leukemia progression in vivo, we used a mouse model of erythroleukemias induced by F-MuLV, in which insertional activation of Fli-1 occurs as early as 40 days post viral injection [44], is the initial event during leukemogenesis [4]. The gene discussed is FLI1; the disease is leukemia.